CompletedNCT00893256
Adding citalopram to risperidone for negative symptoms of schizophrenia
About this title
Read the official source — NCT00893256Medication studyAges 17–50India
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 17 years to 50 years. Other eligibility criteria applied.
- Listed locations
- BangaloreSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 48
- Sponsor
- National Institute of Mental Health and Neuro Sciences, India
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- India
- Age range
- From 17 Years to 50 Years
- Official registry ID
- NCT00893256
- Official title
Show the full official title
Prospective Double-Blind Randomized Comparison Study of Improvement in Negative Symptoms With Risperidone vs Risperidone +Citalopram Combination Therapy in Schizophrenia--a Clinical Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Bangalore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Mental Health and Neuro Sciences, India, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Risperidone, risperidone, Citalopram and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 17 years to 50 years. Other eligibility criteria applied.
